Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(12):1818-1825; doi:10.1093/annonc/mdl300
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
lung cancer |
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
1 Thoracic Oncology Unit, Orbassano, Torino, Italy
2 Pathology Division, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Torino, Italy
3 Response Genetics, Los Angeles, CA, USA
4 University of Southern California, Norris Cancer Center, Los Angeles, CA, USA
5 University of Torino, Department of Clinical & Biological Sciences, Genomics & Informatics Unit, Orbassano, Torino, Italy
* Correspondence to: Dr G. V. Scagliotti, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Torino, Italy. Tel: +39-0119026414; Fax: +39-0119038616; E-mail: giorgio.scagliotti{at}unito.it
Background: Pivotal studies indicate a role of excision repair cross-complementation 1 (ERCC1) gene and ribonucleotide reductase M1 (RRM1) gene in conferring a differential sensitivity to cytotoxic chemotherapy and epidermal growth factor receptor (EGFR) gene has been recently extensively investigated in non-small-cell lung cancer (NSCLC).
Design: Formalin-fixed, paraffin-embedded bronchoscopic/fine needle aspiration biopsies obtained from 70 patients with advanced NSCLC were retrospectively collected to investigate the expression level of ERCC1, RRM1 and EGFR by real-time PCR. Sufficient amounts of messenger RNA (mRNA) were successfully extracted from 61 (87%) specimens, reverse transcribed and amplified with intron-spanning primers. Forty-one patients had stage IV disease and 43 received cisplatin/gemcitabine chemotherapy.
Results: A strong correlation between ERCC1 and RRM1 mRNA levels (rs = 0.624, P < 0.0001) was found. Median survival time in patients with low ERCC1 was significantly longer (17.3 versus 10.9, P = 0.0032 log-rank test) as well as in patients with low RRM1 (13.9 versus 10.9, P = 0.0390 log-rank test). Concomitant low expression levels of ERCC1 and RRM1 (n = 33) were predictive of a better outcome (14.9 versus 10.0, P = 0.0345 log-rank test). Among cisplatin-treated patients, a low ERCC1 level was highly predictive of a longer survival (23.0 versus 12.4, P = 0.0001 log-rank test). No correlation between gene expression levels and histology was reported. No significant correlation between EGFR expression level and survival was found. At multivariate analysis, performance status, response to chemotherapy, presence of weight loss and ERCC1 were independent prognostic factors for survival.
Conclusions: This retrospective study further validates ERCC1 and RRM1 genes as reliable candidates for customized chemotherapy and shows a higher impact on the survival of NSCLC patients treated with cisplatin/gemcitabine for ERCC1. Prospective pharmacogenomic studies represent a research priority in early and advanced NSCLC.
Key words: EGFR, ERCC1, RRM1, cisplatin, gemcitabine, real-time PCR
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Holm, A. Mellemgaard, T. Skov, and B. G. Skov Different Impact of Excision Repair Cross-Complementation Group 1 on Survival in Male and Female Patients With Inoperable Non-Small-Cell Lung Cancer Treated With Carboplatin and Gemcitabine J. Clin. Oncol., September 10, 2009; 27(26): 4254 - 4259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L Ronchi, S. Sbiera, L. Kraus, S. Wortmann, S. Johanssen, P. Adam, H. S Willenberg, S. Hahner, B. Allolio, and M. Fassnacht Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy Endocr. Relat. Cancer, September 1, 2009; 16(3): 907 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Rossi, G. Pelosi, P. Graziano, M. Barbareschi, and M. Papotti Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non--Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments International Journal of Surgical Pathology, June 1, 2009; 17(3): 206 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Saviozzi, P. Ceppi, S. Novello, P. Ghio, M. Lo Iacono, P. Borasio, A. Cambieri, M. Volante, M. Papotti, R. A. Calogero, et al. Non-Small Cell Lung Cancer Exhibits Transcript Overexpression of Genes Associated with Homologous Recombination and DNA Replication Pathways Cancer Res., April 15, 2009; 69(8): 3390 - 3396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Inge, K. D. Coon, M. A. Smith, and R. M. Bremner Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ceppi, S. Novello, A. Cambieri, M. Longo, V. Monica, M. Lo Iacono, M. Giaj-Levra, S. Saviozzi, M. Volante, M. Papotti, et al. Polymerase {eta} mRNA Expression Predicts Survival of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy Clin. Cancer Res., February 1, 2009; 15(3): 1039 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. V. Scagliotti, P. Ceppi, S. Novello, and M. Papotti Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology ASCO Educational Book, January 1, 2009; 2009(1): 431 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Krivak, K. M. Darcy, C. Tian, D. Armstrong, B. E. Baysal, H. Gallion, C. B. Ambrosone, and J. A. DeLoia Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3598 - 3606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Smith, D. Su, I. A. Rigault de la Longrais, P. Schwartz, M. Puopolo, T. J. Rutherford, G. Mor, H. Yu, and D. Katsaros ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy J. Clin. Oncol., November 20, 2007; 25(33): 5172 - 5179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Gazdar DNA Repair and Survival in Lung Cancer -- The Two Faces of Janus N. Engl. J. Med., February 22, 2007; 356(8): 771 - 773. [Full Text] [PDF]
|
|
|
|
|
|
Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer N. Engl. J. Med., February 22, 2007; 356(8): 800 - 808. [Abstract] [Full Text] [PDF]
|
|